Literature DB >> 2568015

Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials.

H R Koelz1.   

Abstract

Randomized clinical trials comparing H2-receptor antagonists, antacids, antacid/alginate and prokinetic drugs with placebo and other substances were analyzed. Symptomatic improvement has been shown for H2-receptor antagonists, antacids in very high doses and prokinetic drugs. H2-receptor antagonists, the present mainstay of reflux therapy, improve esophagitis, but they are insufficient in the treatment of severe esophagitis where omeprazole may become the therapy of choice. The evidence is weak that antacids, antacid/alginate, metoclopramide and domperidone heal esophagitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568015

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  19 in total

Review 1.  Medical management of gastro-oesophageal reflux disease.

Authors:  J S Collins
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

Review 2.  Histamine-2-receptor antagonists in gastro-oesophageal reflux.

Authors:  D G Colin-Jones
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

3.  An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

4.  Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.

Authors:  M L Cloud; W W Offen
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

5.  Diagnosis and treatment of gastro-oesophageal reflux.

Authors:  A E Davies; B K Sandhu
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

6.  Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients.

Authors:  E Kuster; E Ros; V Toledo-Pimentel; A Pujol; J M Bordas; L Grande; C Pera
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

7.  Three year follow up of patients with gastrooesophageal reflux disease.

Authors:  N E Schindlbeck; A G Klauser; G Berghammer; W Londong; S A Müller-Lissner
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 8.  Chest pain and angiographically normal coronary arteries. Implications for treatment.

Authors:  V Mukerji; B D Beitman; M A Alpert
Journal:  Tex Heart Inst J       Date:  1993

Review 9.  Medical treatment of esophageal motility disorders.

Authors:  H D Allescher; W J Ravich
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

Review 10.  A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN).

Authors:  Y Vandenplas; A Ashkenazi; D Belli; N Boige; J Bouquet; S Cadranel; J P Cezard; S Cucchiara; C Dupont; K Geboes
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.